Andy C. Rawstron

18.5k total citations
196 papers, 7.3k citations indexed

About

Andy C. Rawstron is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Andy C. Rawstron has authored 196 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Genetics, 85 papers in Pathology and Forensic Medicine and 80 papers in Immunology. Recurrent topics in Andy C. Rawstron's work include Chronic Lymphocytic Leukemia Research (120 papers), Lymphoma Diagnosis and Treatment (83 papers) and Immunodeficiency and Autoimmune Disorders (60 papers). Andy C. Rawstron is often cited by papers focused on Chronic Lymphocytic Leukemia Research (120 papers), Lymphoma Diagnosis and Treatment (83 papers) and Immunodeficiency and Autoimmune Disorders (60 papers). Andy C. Rawstron collaborates with scholars based in United Kingdom, United States and Italy. Andy C. Rawstron's co-authors include Peter Hillmen, Roger G. Owen, Gareth J. Morgan, Stephen J. Richards, Andrew Jack, Faith E. Davies, Ben Kennedy, Paul Emery, Edward M Vital and J. A. Child and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Andy C. Rawstron

187 papers receiving 7.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andy C. Rawstron United Kingdom	42	3.9k	3.0k	3.0k	2.9k	1.9k	196	7.3k
Morton Coleman United States	47	3.3k 0.8×	4.8k 1.6×	2.1k 0.7×	1.2k 0.4×	1.6k 0.8×	306	8.2k
Ivana N. Micallef United States	45	1.7k 0.4×	3.3k 1.1×	2.9k 1.0×	1.6k 0.5×	1.3k 0.7×	256	7.4k
Francesco Zaja Italy	46	2.2k 0.6×	3.0k 1.0×	2.0k 0.7×	1.2k 0.4×	410 0.2×	187	6.4k
Richard R. Furman United States	51	7.3k 1.9×	7.4k 2.4×	2.3k 0.8×	3.6k 1.2×	2.3k 1.2×	301	11.8k
Iwona Włodarska Belgium	52	2.4k 0.6×	4.3k 1.4×	1.5k 0.5×	1.7k 0.6×	2.2k 1.2×	193	8.6k
Martin Bentz Germany	50	5.0k 1.3×	5.0k 1.6×	1.2k 0.4×	2.2k 0.8×	2.5k 1.3×	123	9.3k
Luis Fayad United States	50	2.7k 0.7×	6.3k 2.1×	1.1k 0.4×	1.7k 0.6×	1.3k 0.7×	334	9.7k
Corrado Tarella Italy	41	1.5k 0.4×	2.8k 0.9×	2.5k 0.8×	1.3k 0.4×	1.0k 0.5×	213	6.2k
Luis F. Porrata United States	43	1.4k 0.4×	2.4k 0.8×	1.7k 0.6×	1.5k 0.5×	835 0.4×	211	5.4k
Francesc Bosch Spain	48	4.3k 1.1×	5.6k 1.8×	1.2k 0.4×	2.1k 0.7×	2.0k 1.0×	243	8.7k

Countries citing papers authored by Andy C. Rawstron

Since Specialization

Citations

This map shows the geographic impact of Andy C. Rawstron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy C. Rawstron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy C. Rawstron more than expected).

Fields of papers citing papers by Andy C. Rawstron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy C. Rawstron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy C. Rawstron. The network helps show where Andy C. Rawstron may publish in the future.

Co-authorship network of co-authors of Andy C. Rawstron

This figure shows the co-authorship network connecting the top 25 collaborators of Andy C. Rawstron. A scholar is included among the top collaborators of Andy C. Rawstron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy C. Rawstron. Andy C. Rawstron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Alexandra, Clare Frobisher, Abraham Varghese, et al.. (2025). COVID ‐19‐related mortality in a real‐world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK 's Haematological Malignancy Research Network. British Journal of Haematology. 208(2). 486–497.

Rawstron, Andy C., David Cairns, Nichola Webster, et al.. (2025). Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.. Blood. 146(Supplement 1). 794–794.

Σταματόπουλος, Κώστας, Šárka Pavlová, Othman Al‐Sawaf, et al.. (2024). Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities. HemaSphere. 8(7). e113–e113. 2 indexed citations

Tute, Ruth M. de, Charlotte Pawlyn, David A. Cairns, et al.. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology. 40(25). 2889–2900. 40 indexed citations

Linley, Adam J., Annalisa D’Avola, Silvia Cicconi, et al.. (2021). Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. Clinical Cancer Research. 27(20). 5647–5659. 4 indexed citations

Lamb, Maxine, Alexandra Smith, Daniel Painter, et al.. (2021). Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. BMJ Open. 11(2). e041296–e041296. 6 indexed citations

Hillmen, Peter, Rebecca H. Boucher, Nichola Webster, et al.. (2020). Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. Blood. 136(Supplement 1). 17–18. 13 indexed citations

Appleby, Niamh, Toby A. Eyre, Maité Cabes, et al.. (2019). The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer. 19(1). 471–471. 19 indexed citations

Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. Journal of Clinical Oncology. 37(30). 2722–2729. 180 indexed citations

10.

Hillmen, Peter, Talha Munir, Andy C. Rawstron, et al.. (2017). Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy. Blood. 130. 428–428. 25 indexed citations

11.

Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2017). The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy.. Haematologica. 102. 311–311. 4 indexed citations

12.

Kwok, Marwan, Andy C. Rawstron, Abraham Varghese, et al.. (2016). Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 128(24). 2770–2773. 95 indexed citations

13.

Elkins, Kristi, Bing Zheng, MaryAnn Go, et al.. (2012). FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma. Molecular Cancer Therapeutics. 11(10). 2222–2232. 69 indexed citations

14.

Feyler, Sylvia, M von Lilienfeld-Toal, Sarah Jarmin, et al.. (2009). CD4⁺CD25⁺FoxP3⁺ regulatory T cells are increased whilst CD3⁺CD4⁻CD8⁻αβTCR⁺ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. British Journal of Haematology. 144(5). 686–695. 121 indexed citations

15.

Rawstron, Andy C., Alberto Órfão, Gema Mateo, et al.. (2007). Report of the European Myeloma Network (EMN) workshop on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica.

16.

Moreton, Paul, et al.. (2003). Achieving a MRD negative response after alemtuzumab for CLL is the best predictor for prolonged survival. Blood. 102(11). 39116. 5 indexed citations

17.

Richards, Stephen J., Andy C. Rawstron, & Peter Hillmen. (2000). Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry. 42(4). 223–233. 111 indexed citations

18.

19.

Pratt, Guy, et al.. (1998). Autologous stem cell transplantation in chronic myeloid leukaemia using Philadelphia chromosome negative blood progenitors mobilised with hydroxyurea and G-CSF. Bone Marrow Transplantation. 21(5). 455–460. 7 indexed citations

20.

McGonagle, Dennis, Andy C. Rawstron, Stephen J. Richards, et al.. (1997). A phase 1 study to address the safety and efficacy of granulocyte colony‐stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis. Arthritis & Rheumatism. 40(10). 1838–1842. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact